Pfizer Inc.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
Only pre-clinical projects with a focus on these areas of interest will be considered for Pfizer support at this time:
• Correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRDnegativity, and response to prior therapy
• Understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS)
• Mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion)
• Correlation between Soluble BCMA and BCMA expression on myeloma cells
• Impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels
• Mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity
• Exploring in-vitro or in-vivo novel combinations with elranatamab (PF06863135)
Full Proposal Grant Application due date: May 17, 2021